Photo from Erman Akkus/X
Aug 27, 2024, 22:10
Erman Akkus: Genome targeted cancer therapies in NCCN guidelines according to the ESMO MCBS and ESCAT
Erman Akkus, Medical Oncology Fellow at Ankara University Faculty of Medicine, shared a post on X:
“Genome targeted cancer therapies in National Comprehensive Cancer Network (NCCN) guidelines according to the ESMO MCBS and ESCAT.
411 recommendations:
- 16% relied on only case reports or pre-clinical studies
- 78% of clinical trials are phase I/II
- 76% of clinical trials are single arm
- In 78%, primary endpoint is ORR
- 60% is ESCAT tier 1
- Only 12% showed substantial clinical benefit (ESMO-MCBS grades 4-5).”
Source: Erman Akkus/X
Authors: Ariadna Tibau, Thomas J Hwang, Jerry Avorn, and Aaron S Kesselheim.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 12:18
Dec 21, 2024, 11:52
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18